poisar

Stock

Regeneron Pharmaceuticals, Inc. REGN

$814.96-2.28%

Overview

REGN market data

Price History

REGN price chart · 1M
O
828.42
H
829.39
L
814.78
C
814.96
Vol
16,513.00
Source
US equities market feed
Observed
Aug 26, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$828.42
Previous Close
$833.98
Day High
$829.39
Day Low
$814.78
52 Week High
$846.52
52 Week Low
$590.96
7 Day Return
-3.09%
30 Day Return
+22.32%
90 Day Return
+31.29%
1 Year Return
+7.57%
Daily Notional Volume
$13.5M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
18.98
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$41.48
Diluted earnings per share over the trailing twelve months.
Beta
0.15
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
0.5%
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
27.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$541.00 – $847.00
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $82.2B · P/B 2.60 · P/S 5.29.

Company News

10 captured
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?The Motley Fool · Aug 21, 2026, 12:15 PM
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder DrugBenzinga · Aug 20, 2026, 1:25 PM
Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain HemorrhageBenzinga · Aug 20, 2026, 11:25 AM
Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans ProgressivaBenzinga · Aug 19, 2026, 6:02 PM
European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent IndicationBenzinga · Aug 18, 2026, 2:46 PM
Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'Benzinga · Aug 13, 2026, 2:41 AM
LibtayoReceives Health Canada Approval for Adjuvant Treatment Of High-Risk Cutaneous Squamous Cell CarcinomaBenzinga · Aug 6, 2026, 3:35 PM
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit – Hagens BermanGlobenewswire Inc · Aug 6, 2026, 11:15 AM
REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate FailureGlobenewswire Inc · Aug 4, 2026, 11:00 AM
Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740Benzinga · Aug 3, 2026, 6:43 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock